



UNIVERSITY OF
SOUTH ALABAMA

TRANSLATIONAL PKPD MODELLING IN SCHIZOPHRENIA

Linking Receptor Occupancy

TRANSLATIONAL PKPD MODELLING IN SCHIZOPHRENIA

Linking Receptor Occupancy
of Antipsychotics to Efficacy and Safety

Venkatesh Pilla Reddy

Venkatesh Pilla Reddy

TRANSLATIONAL PKPD MODELLING
IN SCHIZOPHRENIA
Linking Receptor Occupancy
to Antipsychotics to Efficacy and Safety
Venkatesh Pilla Reddy

This research was performed within the framework of project no. D2-104 of the Dutch Top Institute Pharma. Financial support of the Dutch Top Institute Pharma is greatly appreciated.

Publication of this thesis was financially supported by:

University of Groningen (RUG)
Groningen Graduate School of Sciences (GGSS)
Dutch Top Institute Pharma (www.tipharma.com)

ISBN printed version: 978-90-367-5553-5

ISBN electronic version: 978-90-367-5575-7

Cover Front Page: "Glow of Hope" is a painting by S.L. Haldankar

Printed by: Off Page, Amsterdam (www.offpage.nl)

Copyright © 2012 by Venkatesh Pilla Reddy

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission of the author and the publisher holding the copyright of the published articles.



rijksuniversiteit
 groningen

TRANSLATIONAL PKPD MODELLING IN SCHIZOPHRENIA

**Linking Receptor Occupancy
 of Antipsychotics to Efficacy and Safety**

Proefschrift

ter verkrijging van het doctoraat in de
 Wiskunde en Natuurwetenschappen
 aan de Rijksuniversiteit Groningen
 op gezag van de
 Rector Magnificus, dr. E. Sterken,
 in het openbaar te verdedigen op
 vrijdag 15 juni 2012
 om 11:50 uur

door

Venkatesh Pilla Reddy
 geboren op 1 januari 1976
 te Bangalore, India

*Dedicated to my wife Nisha
 and my son Tejus*

Promotores:

Prof. dr. G.M.M. Groothuis

Prof. dr. M. Danhof

Copromotor:

Dr. J.H. Proost

Beoordelingscommissie:

Prof. dr. M.O. Karlsson

Prof. dr. R.A. Dierckx

Prof. dr. J.A. den Boer

TABLE OF CONTENTS

Chapter 1	Translational PKPD Modelling in Schizophrenia: General Introduction	7
Chapter 2	Scope and Outline of the Thesis	17
Chapter 3	Structural Models Describing Flexible Treatment Effects in Schizophrenia and Other Neuro-psychiatric Disorders	33
Chapter 4	Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Disease Hazard in Flexible Trials of Schizophrenia Clinical Trials	73
Chapter 5	Population Pharmacokinetic-Pharmacodynamic Modelling of Haloperidol in Patients with Schizophrenia using Positive and Negative Syndrome Rating Scale	103
Chapter 6	Pharmacokinetic-Pharmacodynamic Modelling of Antipsychotic Drugs in Patients with Schizophrenia: Part I: the use of PANSS Total Score and Clinical Utility	125
Chapter 7	Pharmacokinetic-Pharmacodynamic Modelling of Antipsychotic Drugs in Patients with Schizophrenia: Part II: the use of subscores of the PANSS score	155
Chapter 8	Sensitivity of Individual Items of the Positive and Negative Syndrome Scale (PANSS) and their Subscore as Biomarkers Between Flexible and Drug Treatment of Schizophrenia	177
Chapter 9	Pharmacokinetic-Pharmacodynamic Modelling of Severity Levels of Extrapyramidal Side Effects with Minko Biomarkers	191
Chapter 10	Translational PKPD modelling in Schizophrenia: Linking Bayesian Estimation of Dose-toxicity in Efficacy and Safety	231
Chapter 11	Discussion and Future Perspectives	255
Chapter 12	Summary	273
Chapter 13	Summarizing (Dissertation Summary)	315
Appendix		
	Acknowledgements	321
	Curriculum Vitae	323
	List of Publications	325
	Declaration of Interests	327

Dedicated to my wife Nisha
and my son Tejus

TABLE OF CONTENTS

Chapter 1	Translational PKPD Modelling in Schizophrenia: General Introduction	9
Chapter 2	Scope and Outline of the Thesis	27
Chapter 3	Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders	33
Chapter 4	Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials	73
Chapter 5	Population Pharmacokinetic-Pharmacodynamic Modelling of Haloperidol in Patients with Schizophrenia using Positive and Negative Syndrome Rating Scale	105
Chapter 6	Pharmacokinetic-Pharmacodynamic Modelling of Antipsychotic Drugs in Patients with Schizophrenia: Part I: the use of PANSS Total Score and Clinical Utility	125
Chapter 7	Pharmacokinetic-Pharmacodynamic Modelling of Antipsychotic Drugs in Patients with Schizophrenia: Part II: the use of subscales of the PANSS score	155
Chapter 8	Sensitivity of Individual Items of the Positive and Negative Syndrome Scale (PANSS) and Items Subgroups to Differentiate Between Placebo and Drug Treatment in Schizophrenia	177
Chapter 9	Pharmacokinetic-Pharmacodynamic Modelling of Severity Levels of Extrapyramidal Side Effects with Markov Elements	201
Chapter 10	Translational PKPD modelling in Schizophrenia: Linking Receptor Occupancy of Antipsychotics to Efficacy and Safety	221
Chapter 11	Discussion and Future Perspectives	255
Chapter 12	Summary	277
Chapter 13	Samenvatting (Dutch Summary)	285
Addendum		293
	Acknowledgements	295
	Curriculum Vitae	297
	List of Publications	298
	Awards and Achievements	302